186-OR: Safety and Tolerability of the Next Generation Aldose Reductase Inhibitor (ARI) AT-001 Supports Initiation of the Pivotal Trial in Diabetic Cardiomyopathy (DbCM)

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 186-OR
Author(s):  
RICCARDO PERFETTI ◽  
FRANCESCA C. LAWSON ◽  
JULIO ROSENSTOCK ◽  
JAMES JANUZZI ◽  
SHOSHANA SHENDELMAN ◽  
...  
Keyword(s):  
Aldose Reductase ◽  
Diabetic Cardiomyopathy ◽  
Reductase Inhibitor ◽  
Aldose Reductase Inhibitor ◽  
Pivotal Trial ◽  
Next Generation

1080-P: Addressing the Safety Challenges of Aldose Reductase Inhibition: Development of AT-001 for Diabetic Cardiomyopathy, a Potent and Selective Next Generation Aldose Reductase Inhibitor

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1080-P
Author(s):  
RICCARDO PERFETTI ◽  
GAUTHAM YEPURI ◽  
NOSIRUDEEN A. QUADRI ◽  
AMEEN F. GHANNAM ◽  
RAVICHANDRAN RAMASAMY ◽  
...  
Keyword(s):  
Aldose Reductase ◽  
Diabetic Cardiomyopathy ◽  
Reductase Inhibitor ◽  
Aldose Reductase Inhibitor ◽  
Next Generation ◽  
Aldose Reductase Inhibition

462-P: AT-001, a Next Generation Aldose Reductase Inhibitor with Improved Selectivity and Specificity, Protects from Cellular Damage Associated with Hyperglycemia

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 462-P
Author(s):  
RICCARDO PERFETTI ◽  
GAUTHAM YEPURI ◽  
NOSIRUDEEN A. QUADRI ◽  
RAVICHANDRAN RAMASAMY ◽  
AMEEN F. GHANNAM ◽  
...  
Keyword(s):  
Aldose Reductase ◽  
Reductase Inhibitor ◽  
Aldose Reductase Inhibitor ◽  
Cellular Damage ◽  
Next Generation

Targeted co-delivery of the aldose reductase inhibitor epalrestat and chemotherapeutic doxorubicin via a redox-sensitive prodrug approach promotes synergistic tumor suppression

2019 ◽  
Vol 7 (7) ◽  
pp. 2889-2906 ◽  
Author(s):  
Venkatesh Teja Banala ◽  
Sandeep Urandur ◽  
Shweta Sharma ◽  
Madhu Sharma ◽  
Ravi P. Shukla ◽  
...  
Keyword(s):  
Aldose Reductase ◽  
Tumor Suppression ◽  
Reductase Inhibitor ◽  
Aldose Reductase Inhibitor ◽  
Down Regulation ◽  
Redox Responsive

Redox responsive epalrestat prodrug micelles facilitate synergistic concentrations of doxorubicin with an advantage of CD44 down-regulation and reduced cardiotoxicity.

In vitro retinal and erythrocyte polyol pathway regulation by hormones and an aldose reductase inhibitor

1991 ◽  
Vol 14 (1) ◽  
pp. 29-35 ◽  
Author(s):  
N. Hotta ◽  
H. Kakuta ◽  
N. Koh ◽  
H. Fukasawa ◽  
T. Yasuma ◽  
...  
Keyword(s):  
Aldose Reductase ◽  
Reductase Inhibitor ◽  
Polyol Pathway ◽  
Aldose Reductase Inhibitor ◽  
Pathway Regulation
Sign in / Sign up

Export Citation Format

Share Document